1-(2,3-dihydro-1H-inden-1-yl)ethanol | 272126-80-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1-(2,3-dihydro-1H-inden-1-yl)ethanol
• 英文别名: 1-indan-1-yl-ethanol；Methyl-α-hydrindyl-carbinol；1-(α-Oxy-aethyl)-hydrinden；1-Indan-1-yl-aethanol
• CAS: 272126-80-4
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: MEKDUGFLAOZSOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2,3-dihydro-1H-inden-1-yl)ethanol 生成 1-ethylidene-2,3-dihydroindene
  参考文献：
  名称：

  Vertebral Artery Dissection and Migraine Headaches in Children

  摘要：

  后循环中风在儿童中并不常见。在椎基底动脉损害中，椎动脉夹层仍然是一种罕见的诊断。我们报告了一例8岁男孩的病例，患有偏头痛症状，出现了急性小脑体征和激动，之后出现了双侧小脑半球多次梗死。椎动脉造影显示左侧椎动脉夹层，基底动脉在其起始部位稍远处被闭塞。回顾了椎动脉夹层的风险因素，重点强调与偏头痛的关联。还介绍了用于诊断夹层的影像学研究。这个病例显示了在儿童患有不典型偏头痛且出现新的神经学表现时，考虑动脉壁夹层的重要性。

  DOI：

  10.1177/088307380001501011
• 作为产物：
  描述：

  1-inden-1-yl-ethanol 在 乙醚 、 铂 作用下， 生成 1-(2,3-dihydro-1H-inden-1-yl)ethanol
  参考文献：
  名称：

  Vertebral Artery Dissection and Migraine Headaches in Children

  摘要：

  后循环中风在儿童中并不常见。在椎基底动脉损害中，椎动脉夹层仍然是一种罕见的诊断。我们报告了一例8岁男孩的病例，患有偏头痛症状，出现了急性小脑体征和激动，之后出现了双侧小脑半球多次梗死。椎动脉造影显示左侧椎动脉夹层，基底动脉在其起始部位稍远处被闭塞。回顾了椎动脉夹层的风险因素，重点强调与偏头痛的关联。还介绍了用于诊断夹层的影像学研究。这个病例显示了在儿童患有不典型偏头痛且出现新的神经学表现时，考虑动脉壁夹层的重要性。

  DOI：

  10.1177/088307380001501011

文献信息

• [EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2018026371A1

  公开（公告）日：2018-02-08

  Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  公开了化学式I的化合物，以及含有这些化合物的药物组合物。还公开了治疗患有神经系统或精神障碍的患者的方法。这些障碍包括抑郁症、躁郁症、疼痛、精神分裂症、强迫症、成瘾、社交障碍、注意力缺陷多动障碍、焦虑障碍、自闭症、认知障碍，或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及在神经系统疾病如阿尔茨海默病和帕金森病中的睡眠障碍。
• Dynamic Kinetic Asymmetric Amination of Alcohols Assisted by Microwave: Stereoconvergent Access to Tetralin- and Indane-Derived Chiral Amines
  作者：Zi-Qiang Rong、Zhaoyuan Yu、Cheng Weng、Li-Cheng Yang、Shenci Lu、Yu Lan、Yu Zhao

  DOI：10.1021/acscatal.0c02468

  日期：2020.8.21

  alcohols to produce the corresponding chiral amines that are important structural motifs in numerous biologically active entities. By the use of an iridium/phosphoric acid cooperative catalytic system, a range of easily accessible alcohol substrates, as a mixture of four stereoisomers, can be converted in a convergent fashion to the valuable α-branched chiral amines with good to high diastereo- and enantioselectivity

  在此，我们报道了四氢化萘和茚满衍生的醇的微波辅助催化对映选择性胺化反应，以产生相应的手性胺，该手性胺是许多生物活性实体中的重要结构基序。通过使用铱/磷酸协同催化系统，可以将多种易于获得的醇底物（四种立体异构体的混合物）以会聚方式转化为有价值的α-支化手性胺，并具有良好的至高非对映体和高对映体。对映选择性。还对催化反应进行了系统的DFT计算，它为醇的动态动力学不对称胺化提供了途径的完整图以及非对映和对映选择性的来源。
• Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11186564B2

  公开（公告）日：2021-11-30

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  式 I 的化合物： 以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。
• DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20190194163A1

  公开（公告）日：2019-06-27

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.